MRUS - Merus announces benefit of Zenocutuzumab in pancreatic cancer

Merus N.V. (MRUS) highlighted the benefit of Zenocutuzumab in pancreatic cancer with the announcement of an abstract regarding the experimental cancer therapy which is part of a presentation at the American Society of Clinical Oncology ((ASCO)) 2021 Annual Meeting.The interim data as of January 12, 2021 cutoff related to phase 1/2 eNRGY trial and Early Access Program ((EAP)) of zenocutuzumab ((Zeno)) in patients with NRG1+ cancers.The trial consisted of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors.Out of 55 patients who were treated with Zeno 33 were evaluable for response. Tumor regression was seen in 25 out of 33 patients with confirmed partial responses in 9 of 33 (27% ORR).The effect was notable in the cohort of pancreatic cancer with confirmed partial responses seen in 4 of 10 patients (40% ORR).Zeno, a bispecific antibody was well tolerated with the majority of adverse events being mild

For further details see:

Merus announces benefit of Zenocutuzumab in pancreatic cancer